Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 08, 2026 09:52 ET | Source: BCC Research LLC

AI Technology Transforms Cannabis Industry as Leading Operators Drive Adoption to Enhance Yields and Compliance

According to BCC Research, AI is transforming the cannabis value chain from cultivation and manufacturing to distribution, retail, and medical use.
May 08, 2026 07:30 ET | Source: Custom Market Insights

[Latest] Global Surgical Case Carts Market Size/Share Worth USD 686.99 Million by 2035 at a 4.04% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, May 08, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Surgical Case Carts Market Size, Trends and Insights By Type (Open Case Cart,...
May 08, 2026 07:00 ET | Source: MapLight Therapeutics, Inc.

MapLight Therapeutics to Participate in Upcoming Investor Conferences

SAN FRANCISCO and BOSTON, May 08, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT) today announced that members of its management team will participate in the following investor...
May 08, 2026 05:50 ET | Source: Research and Markets

Bioelectronic Medicine Research Report 2026 - Global Market Analysis, Competitive Landscape, Opportunities, and Forecasts, 2021-2025 & 2025-2031

Dublin, May 08, 2026 (GLOBE NEWSWIRE) -- The "Bioelectronic Medicine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F" has been added to ResearchAndMarkets.com's...
May 07, 2026 20:44 ET | Source: Odyssey Therapeutics Inc

Odyssey Therapeutics Announces Pricing of Upsized Initial Public Offering

Odyssey Therapeutics, Inc. announces pricing of its upsized IPO of 15,500,000 shares of its common stock at an IPO price of $18 per share.
May 07, 2026 16:05 ET | Source: LeonaBio, Inc.

LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update

Advancing Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator, a Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations ...